ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.746,76
0,39%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Viking Therapeutics Inc (VKTX)

  7. Viking Therapeutics Inc (VKTX) News

VKTX

Viking Therapeutics (VKTX)

Viking Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VKTX
DatumZeitQuelleÜberschriftSymbolFirma
30/05/202422h03PR Newswire (US)Viking Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:VKTXViking Therapeutics Inc
22/05/202423h12Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:VKTXViking Therapeutics Inc
22/05/202422h33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
24/04/202422h05PR Newswire (US)Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
24/04/202413h31IH Market NewsU.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures TradingNASDAQ:VKTXViking Therapeutics Inc
17/04/202422h05PR Newswire (US)Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024NASDAQ:VKTXViking Therapeutics Inc
26/03/202412h03PR Newswire (US)Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735NASDAQ:VKTXViking Therapeutics Inc
05/03/202401h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
05/03/202401h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
04/03/202422h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
04/03/202422h45PR Newswire (US)Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:VKTXViking Therapeutics Inc
01/03/202422h13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
29/02/202402h50PR Newswire (US)Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
27/02/202423h21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
27/02/202422h19PR Newswire (US)Viking Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
27/02/202413h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
27/02/202413h03PR Newswire (US)Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
10/02/202402h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
09/02/202422h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
09/02/202401h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
09/02/202401h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
08/02/202422h56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
08/02/202422h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
07/02/202423h33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
07/02/202423h24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VKTXViking Therapeutics Inc
07/02/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
07/02/202422h05PR Newswire (US)Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
01/02/202402h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
31/01/202423h32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
31/01/202422h05PR Newswire (US)Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024NASDAQ:VKTXViking Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VKTX

Kürzlich von Ihnen besucht

NASDAQ
ABAAUXX
Goldman Sachs Bank Usa C...
BIT
UC59VU
Unicredit Bank
COIN
BBPPETH
LSE
BB36
Barclays 27
LSE
EML
Emmerson
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten